1Turktas H, Unsal M, Tulek N, et al. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazidand and pyrazinamide) or viral hepatitis.Tuber Lung Dis, 1994, 75: 58-60.
2Jasmer RM, Daley CL. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? Am J Respir Crit Care Med,2003, 167: 809-810.
3Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf, 2001, 24: 483-490.
4Kunimoto D, Warman A, Beckon A, et al. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity. Clin Infect Dis, 2003, 36: 158-161.
5Castro KG, Jereb JA, Koppaka VR, et al. Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection. Chest, 2003, 123: 967.
6Huang YS,Chern HD,Su WJ,et al.Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.Hepatology,2002,35(4):883-839
7Huang YS,Chern HD,Su WJ,et al.Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.Hepatology,2003,37(4):924-930
8Sharma SK,Balamurugan A,Saha PK,et al.Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.Am J Respir Crit Care Med,2002,166(7):916-919
9Yee D,Valiquette C,Pelletier M,et al.Incidence of serious side from first-line antituberculosis drugs among patients treated for active tuberculosis.Am J Respir Crit Care Med,2003,167(11):1472-1477
10Tiwari VK.Alcoholic hepatic impairment complicating treatment with hepatotoxic antituberculosis drugs.J Indian Med Assoc,1996,94(9):347-348
